SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer revenue guidance, a reduced advertising outlook, and concerns about slowing growth, prompting analyst downgrades and price-target cuts. Traders are split between viewing the outlook and competition concerns as signs of a deeper growth problem and treating the selloff as an overreaction and buying opportunity.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro sharply raised its preliminary fiscal Q1 outlook on stronger AI-platform demand and improved gross-margin expectations, driving a rally. Traders largely welcomed the demand signal and speculated about a short squeeze, while skeptics questioned whether margins, cash flow and execution can sustain the move.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong third-quarter results, including its first profit as a public company and rapid AI-compute growth, prompted a rally and a wave of analyst upgrades. Traders are broadly upbeat, while skeptics point to heavy capital spending and upcoming share unlocks; a possible Tesla merger is also being discussed but remains exploratory.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&Ts earnings beat and higher outlook failed to prevent a selloff, with traders pointing to postpaid phone additions falling short of expectations. The reaction is debated as either concern about subscriber momentum and lingering SpaceX competition or an overreaction to otherwise solid results, with some investors buying the dip.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention amid persistent share-price weakness despite community references to ORLADEYO growth and profitable results, fueling criticism of management and calls for buybacks or a sale. Some traders point to future navenibart and Netherton data and continued ORLADEYO growth as potential catalysts, while skeptics focus on dilution, debt and uncertainty around the companys acquisition-led strategy.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives preferred-stock offering and continued Bitcoin purchases are driving discussion, with bulls viewing the financing as fuel for treasury growth while skeptics warn that dilution and preferred-dividend obligations could weigh on common shareholders.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings have traders focused on Google Cloud growth and whether AI investments can generate returns, amid widespread concern about heavy capital spending and speculation it could rise further. The debate is split between dip-buyers citing Alphabets AI and cloud businesses and bearish traders worried about spending, search disruption, and the shares persistent weakness.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Early Phase 1 azer-cel findings in progressive MS are the main focus, with traders highlighting reported deep B-cell depletion and disability or MRI signals as a potential growth story beyond BRIUMVI. The reaction is broadly optimistic but tempered by the small, preliminary study and uncertainty about whether the data will translate into meaningful clinical benefit; some also note the stocks muted, choppy response.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is drawing attention for its sharp pullback and weak price action ahead of earnings, with traders watching whether cloud growth and AI investment can translate into returns. The discussion is split between dip-buyers citing its AI and quantum-computing progress and bearish traders focused on underperformance, technical support, and heavy capital spending.

TOSHI

TOSHIs sharp rebound and rising trading activity have sparked breakout chatter, with traders watching a stubborn resistance level and speculating about a short squeeze. The bullish momentum is disputed by holders pointing to failed breakouts, weak price action and dependence on a broader crypto-market recovery; listing and announcement talk remains unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.read more...

CMND Stock Set For Biggest Intraday Gains In Over Three Years  — Here’s Why Retail Is Eyeing Further Upside

Equity

Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.

Silo Pharma Rallies After Securing Key Patent Allowance

Silo Pharma shares are trading higher Tuesday after the EPO signaled intent to grant a patent for its serotonin 4 receptor stress application.read more...

Why Did SILO Stock Soar 85% Today? 

The European Patent Office granted a patent for the company’s novel 5-HT4 Post-Traumatic Stress Disorder (PTSD) prevention therapy.


Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket

SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.read more...

Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline UnitedHealth, Silo Pharma, Phillips 66 In Focus

U.S. stocks rose on Tuesday, following Monday's advances.read more...

Levi Strauss, Greenbrier And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures down, investors should watch Levi Strauss, Silo Pharma, Greenbrier, Mach Natural Resources, and Phoenix Education Partners.read more...

Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know

Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.read more...

Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment

The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.

After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025

Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.

This account has been verified as an official SILO representative.

Verified Account

Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

SILO Pharma Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Trump also allocated $50 million in federal funding for related research.</li><li>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines.</li><li>Meanwhile, investors are also tracking Silo Pharma, which is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder.</li></ul>Shares of Clearmind Medicines (CMND) surged nearly 65% in pre-market trading on Monday, putting the stock on track for its biggest intraday gain since August 2022, after U.S. President Donald Trump signed an executive order to accelerate access to psychedelic-based treatments.Separately, Clearmind Medicine, on Monday, said its drug CMND-100 met the main goal in an early-stage trial for Alcohol Use Disorder. The treatment showed strong safety, with no serious side effects reported, even at higher doses.<h2 class="st-heading-2">$50M PTSD Boost</h2>On Saturday, Trump signed an executive order to accelerate research and access to psychedelic-based therapies, bringing renewed attention to treatments for post-traumatic stress disorder (PTSD). The order directs the U.S. Food and Drug Administration to fast-track the review of drugs such as Ibogaine, while allocating $50 million in federal funding for related research.Ibogaine, derived from a Central and West African shrub, remains a Schedule I substance in the U.S., though interest is rising among veteran groups exploring its therapeutic potential. Officials say the move could pave the way for reclassification if clinical trials prove successful, with decisions potentially coming as early as this summer.<h2 class="st-heading-2">All Eyes On Clearmind’s Ibogaine Combination Therapy</h2>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines, a type of fatty acid amide. The patent builds on Clearmind’s collaboration with SciSparc, in which both companies are developing combination therapies pairing psychedelic compounds with molecules such as Palmitoylethanolamide to improve treatment outcomes.Ibogaine has shown promise in clinical studies for treating opioid, cocaine, and other substance use disorders, making it a potential anti-addiction therapy.<a href="https://stocktwits.com/symbol/SILO">SILO stock</a> was down 3% at the time of writing.<h2 class="st-heading-2">Silo’s SPC-15 Development Gets A Boost</h2>Meanwhile, Silo Pharma (SILO) also generated a strong buzz after Trump’s order. The firm is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder. The treatment uses a fast nose-to-brain delivery approach. It is being developed under a faster regulatory pathway, the firm added.“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions. We believe Silo is well positioned with SPC-15 and its broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment,” said Eric Weisblum, CEO of Silo Pharma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CMND">CMND</a> on Stocktwits turned ‘extremely bullish, while sentiment for SILO was ‘bullish.’ Message volumes for CMND were ‘extremely high,’ a whopping 535% increase over the past 24 hours, according to Stocktwits data.One user tracking CMND saw the $1.35-$1.37 level as key resistance.<stembedurl>https://stocktwits.com/minimalistreview/message/650748815</stembedurl>Another user highlighted CMND’s “good results,” adding that the stock could climb over $2.<stembedurl>https://stocktwits.com/Maik237/message/650748439</stembedurl>Year-to-date, CMND shares have declined by more than 66%, while SILO stock has climbed by around 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump speaks during a news conference in James S. Brady Press Briefing Room of the White House on April 06, 2026 in Washington, DC. (Photo by Alex Wong/Getty Images)

Clearmind Medicine Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.20
Prev Close	$1.20
Open	$1.19
Dividend Yield	0.00%
50-Day Moving Average	$2.06
Beta	0.91
Avg. Volume	53,671.09
PE Ratio	-0.22

52-Week High	$10.43
52-Week Low	$1.10
Market Capitalization	$1.91M
EPS (Annual)	-$7.57
Price to Book	0.28
Revenue Per Employee	$24,034.00

Feed

News

Sentiment

Fundamentals

Info

SILO Fundamentals